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ABSTRACT
Transient receptor potential melastatin 7 (TRPM7) functions as a Mg2+/Ca2+-
permeable channel fused with a kinase domain and regulates various physical 
processes and diseases. However, its effects on pathogenesis of human bladder 
cancer (BCa) has not been clarified yet. Our microarray analysis has suggested that 
calcium signaling pathway is connected with bladder cancer via MAPK pathway. 
Therefore, we aim to investigate the mechanism of TRPM7 in BCa tumorigenesis by 
using BCa tissues compared with normal bladder epithelium tissues, as well as using 
distinct BCa cell lines (EJ, 5637 and T24). We observed increased TRPM7 expression 
and dysregulation of proteins involved in Epithelial-Mesenchymal Transition (EMT) 
in BCa tissues. Moreover, knockdown of TRPM7 in BCa cells reversed the EMT status, 
accompanied by increase of reactive oxygen species (ROS). Furthermore, TRPM7 
deficiency could inhibit BCa cell proliferation, migration and invasion, as well as 
induce p-ERK1/2 and suppress PI3K/AKT at the protein level. Downregulation of 
TRPM7 promoted cell cycle arrest at G0/G1 phase and apoptosis in vitro, which 
could be recovered by pre-treatment with U0126 to deactivate ERK1/2, suggesting 
a close correlation between TRPM7 and the MAPK signaling pathway. Furthermore, a 
NOD/SCID mouse model transplanted using the BCa cells was established, revealing 
delayed tumor growth by reduced protein activity and mRNA transcription of TRPM7 
in vivo. Our results suggested TRPM7 might be essential for BCa tumorigenesis by 
interfering BCa cell proliferation, motility and apoptosis. 
INTRODUCTION
Bladder cancer (BCa) is one of the most common 
cancers worldwide [1]. Despite recent progress, the 
molecular mechanism underlying BCa pathogenesis 
remains to be further elucidated. Therefore, our group 
has generated a microarray analysis using total RNA 
isolated from several bladder cancer tissues comparing 
with normal bladder epithelium [2], suggesting calcium 
signaling pathway was linked with bladder cancer via 
MAPK signaling pathway, which was connected with cell 
cycle. 
Mitogen-activated protein kinases (MAPKs) play 
a key role in signal transduction from cell membrane 
to nucleus in response to a wide range of stimuli and 
are involved in the regulation of cell proliferation [3], 
survival, differentiation [4] and apoptosis [5]. Importantly, 
aberrant regulation of MAPK could contribute to cancer 
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and other human diseases, including bladder cancer 
[6, 7]. Many studies have suggested that intracellular or 
extracellular calcium disorders might induce abnormal 
activation or deactivation of MAPK cascades [8, 9] and 
consequently initiate cancer development [10]. A recent 
publication using pathway network analyses revealed a 
major overlaps with various diseases and convergence 
upon MAPK and calcium signaling as well [11]. Studies 
using U0126, a selective MAPK kinase (MKK) inhibitor 
[12], have revealed a major effect on the deactivation of 
ERK1/2 [13] possibly even affecting MAPK-mediated 
mitochondrial-derived [14] and endoplasmic reticulum 
stress induced apoptosis [15]. 
Transient receptor potential melastatin 7 (TRPM7) 
is a member of ‘‘chanzymes’’, which function as a Mg2+/
Ca2+-permeable channel fused with a kinase. TRPM7 
has been reported to be ubiquitously expressed in 
various human tissues [16–18], suggesting that it could 
be implicated in important physiological processes 
such as cellular Mg2+ homeostasis [18], cell viability 
and growth [19], anoxic neuronal cell death [20], and 
cell adhesion [21]. Recent studies indicated a close 
correlation between TRPM7 and cancer, demonstrating 
its involvement in retinoblastoma [22], gastric cancer 
[23], breast cancer [24–27], nasopharyngeal carcinoma 
[28], pancreatic cancer [29], prostate cancer [30], and 
ovarian carcinoma [31]. Our previous studies have 
suggested that knockdown of TRPM8, another important 
subtype of the TRPM family, could inhibit proliferation 
of osteosarcoma and prostate cancer cells [32, 33]. In 
addition, our studies have suggested that TRPM7 affects 
kidney injury [34], revealing a correlation between the 
TRPM family and cell ability [35], cell growth as well 
as Epithelial-Mesenchymal Transition (EMT) [36], 
which was involved in malignancy of tumor. Another 
publication has reported that during stress condition, 
such as brain ischaemia, TRPM7 could control the 
level of reactive oxygen species (ROS) [37], which 
could have a Cross Talk with the EMT [38]. TRPM7 
has been reported to be expressed in human and mouse 
urothelium [39, 40], as well as in MBT-2 mouse bladder 
cancer cells and T24 human bladder cancer cells [41], 
but its effect and mechanism in human bladder cancer 
remain largely unknown. Therefore, we hypothesized 
that TRPM7, which is involved in the calcium signaling 
pathway, could affect bladder cancer by the MAPK 
signaling pathway to trigger BCa cell cycle arrest and 
apoptosis. We aim to identify the alteration of TRPM7 
and related proteins involved in the EMT regulation 
using BCa tissues in vivo, and to observe its effects 
on EMT, cell migration/invasion, apoptosis and cell 
cycle in distinct BCa cell lines in vitro for a potential 
strategy of rescue experiment, as well as to analyze 
the influence of tumor growth using nude mice in vivo 
with deactivated TRPM7 and downregulated TRPM7 at 
transcriptional level. 
RESULTS
Microarray analysis revealed calcium and 
MAPK signaling pathways as central regulators 
in BCa development 
Three BCa tissues (stage II) and three normal bladder 
tissues were collected for alterations of mRNA by microarray 
analysis (Approval in Supplementary Information S1), 
suggesting 1338 genes (fold change > 1.5) (Supplementary 
Information S2) and 146 signaling pathways were 
significantly affected in the BCa tissues (Supplementary 
Information S3). Using a GCBI analysis tool, a pathway 
network connected to BCa was generated (Figure 1), 
indicating that a calcium signaling pathway was correlated 
with BCa via the MAPK signaling pathway connected with 
cell cycle regulation, as well as a central role of calcium and 
MAPK signaling pathways involved in the development 
of BCa. In addition, by annotation and overrepresentation 
analysis using our raw microarray data and DAVID database, 
we observed the genes involved in calcium signaling pathway 
were altered (Supplementary Figure S1A), accompanied 
by significantly upregulation of CALM, CaN and CAMK 
under the deficiency of TRPM7 in vitro (Supplementary 
Figure S1B–S1C). Therefore, we would like to investigate 
the alterations of the genes and proteins related with the 
pathways using bladder tissues and distinct BCa cell lines. 
Induction of TRPM7 and dysregulation of EMT 
markers in BCa tissues 
Immunofluorescence staining using ten BCa tissues 
and ten normal bladder tissues revealed a strong increase 
of OCT-4 in the cytoplasmic region of the BCa tissues 
(representative staining in Figure 2C–2D). Distinct human 
BCa cell lines (from high malignancy to low malignancy: 
T24, 5637, EJ, UM-UC-3, BIU-87, RT-4) and immortalized 
normal uroepithelial cell line (SV-HUC-1) exhibited 
a downregulation tendency of OCT-4 by Western blot 
analysis (Figure 2B), suggesting OCT-4 could be a marker 
for bladder cancer. qRT-PCR revealed that transcription of 
TRPM7 was upregulated in the BCa tissues compared with 
the normal bladder tissues (Figure 2A). TRPM7 was also 
induced in cytomembrane of the OCT4-positive cells in 
the BCa tissues (representative staining in Figure 2E a-b). 
Immunofluorescence analysis also suggested that distribution 
of proteins (E-cadherin and N-cadherin) involved in EMT 
process was strongly altered (representative staining in 
Figure 2E c-f). We observed a reduction of E-cadherin 
(Figure 2E c-d) and an increase of N-cadherin (Figure 2E 
e-f) in the OCT-4 positive cells in BCa tissues. 
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Downregulation of TRPM7 reversed 
dysregulation of EMT markers in vitro
To investigate the effects of TRPM7 in BCa, 
a model of TRPM7 deficiency in distinct BCa cell 
lines (T24, EJ and 5637) was established by siRNA 
transfection. The knockdown efficiency of the siRNA 
was validated by qRT-PCR (Figure 3B), Western blot 
analysis (Figure 3A), and immunofluorescence staining 
(representative staining in Figure 3C), indicating TRPM7 
was remarkably silenced both at gene transcription and 
translation levels in the three BCa cells transfected by 
the siRNA. In contrast to the decrease of E-cadherin 
and increase of N-cadherin noticed in the BCa tissues 
(Figure 2E c-f). Knockdown of TRPM7 triggered strong 
upregulation of the epithelial marker E-cadherin and 
considerable downregulation of the two mesenchymal 
markers N-cadherin and Vimentin, revealed by Western 
blot analysis (Figure 3D) and immunofluorescence 
staining (representative staining in Figure 3E–3G), 
suggesting reduced TRPM7 could alleviate malignancy 
of the BCa cells.
Figure 1: Microarray analysis using mRNA isolated from BCa tissues and normal bladder epithelium tissues. From 
the microarray results, 1338 genes (fold change > 1.5, Supplementary Information 2) and 146 signaling pathways (Supplementary 
Information 3) were screened out. Gene ontology (GO) and Go-map network analysis by using the GCBI analysis tool suggested the 
calcium signaling pathway was at a central position associated with bladder cancer via the MAPK signaling pathway.
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Induction of ROS in BCa cells with TRPM7 
deficiency
The status of ROS in the BCa cells (T24 and EJ) 
were measured by flow cytometry analysis (Supplementary 
Figure S2A) and fluorescence staining (Supplementary 
Figure S2C). Statistical analysis (Supplementary Figure S2B) 
revealed a significantly increase ROS in the siTRPM7-treated 
BCa cells by the flow cytometry measurement. Western blot 
analysis indicated an increased protein abundance of Catalase 
and SOD2 in the BCa cells with downregulated TRPM7 
(Supplementary Figure S2D). 
TRPM7 deficiency impaired BCa cells motility 
and invasion via the PI3K/AKT pathway
The relationship between TRPM7 and BCa cell 
motility and invasion was investigated using transwell 
and wound healing assays. Transwell assay suggested 
that knockdown of TRPM7 in BCa cells could reduce cell 
migration and invasion (Figure 4A), which was confirmed 
by statistically analysis in Figure 4B–4C. Moreover, 
wound healing assay revealed that TRPM7 deficiency 
in BCa cells could reduce the number of migrated cells 
(Figure 4D). The gap closure (%) was statistically 
analyzed (Figure 4E). Furthermore, downregulation of 
p-FAK and MMP2/9 in BCa cells with siTRPM7 was 
noticed (Figure 4F). Interestingly, we have also observed 
the PI3K/AKT signaling pathway, a downstream of FAK 
[42], was affected by TRPM7 deficiency as well, revealing 
a strong reduction of p-PI3K and p-AKT (Figure 4F). 
Knockdown of TRPM7 triggered G0/G1 phase 
cell cycle arrest and apoptosis in the BCa cells
CCK-8 assay revealed that TRPM7 deficiency 
induced inhibition of cell growth, compared with the 
parental and siCON cells (Figure 5A). To better understand 
the underlying mechanism, the effects of TRPM7 on cell 
cycle (Figure 5B) and apoptosis (Figure 6A–6B) were 
analyzed using flow cytometry analysis. Compared with 
the control cells, knockdown of TRPM7 in the BCa cells 
triggered cell cycle arrest at G0/G1 phase (statistically 
analyzed in Figure 5B) as well as a reduction in the 
Figure 2: TRPM7 is upregulated in the BCa tissues and correlated with EMT markers. (A) qRT-PCR analysis of relative 
gene expression of TRPM7 in total RNA isolated from ten BCa tissues at stage II, comparing with ten normal bladder tissues. Significance 
of TRPM7 expression difference was analyzed using T-test. *p < 0.05. (B) Western blot analysis of OCT-4 protein abundance in the human 
BCa cell lines (T24, 5637, EJ, UM-UC-3, BIU-87, RT-4) and immortalized normal uroepithelial cell line (SV-HUC-1), cell types and 
protein masses were indicated. (C–D) Representative immunofluorescence staining of OCT-4 (red) in the BCa tissue (D) comparing with 
the normal bladder tissue (C). Nuclears were stained by DAPI (blue). The images were photographed by fluorescence microscopy. The 
scale bar for C and D is 25 μm. (E) Representative double immunofluorescence staining of TRPM7, E-cadherin and N-cadherin (green) 
in the BCa tissues (b, d, f) comparing with normal bladder tissues (a, c, e). OCT-4 (red) was used as a marker of BCa cells, suggesting 
upregulation of TRPM7 and N-cadherin in the OCT-4 positive BCa cells (b and f), whereas a downregulation of E-cadherin (d). Nuclears 
were stained by DAPI (blue). The scale bar for E (a-f) is 50 μm.
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proportion of cells in S phase. Indeed, cell cycle related 
proteins such as Cyclin D1 and CDK2/4 were decreased 
in the BCa cells with TRPM7 knockdown (Figure 5C). 
Moreover, TRPM7 deficiency resulted in a significant 
increase of the apoptotic BCa cells (Figure 6A–6B). We 
have analyzed the alterations of proteins involved in the 
apoptosis by Western blot (Figure 6C–6D), exhibiting 
upregulation of the apoptosis inducer BAX [43, 44] and 
downregulation of the apoptosis inhibitor BCL2 [45, 46] 
in the siTRPM7-treated BCa cells. Furthermore, pro-
Figure 3: Knockdown of TRPM7 reversed EMT status and alleviated malignancy in BCa cells. (A–C) Efficiency of TRPM7 
knockdown by siRNA treatment in distinct BCa cells (T24, EJ, 5637) was verified by Western blot, qRT-PCR and double immunofluorescence 
staining analysis. (A) Western blot analysis revealed a strongly decreased protein abundance of TRPM7 by the siTRPM7 treatment, 
comparing with parental and siCON treatment. GAPDH was used as a loading control (cell types, treatment of siRNA and protein masses 
were indicated). (B) The relative gene expression of TRPM7 after siRNA treatment was analyzed by qRT-PCR, indicating a significantly 
downregulation of TRPM7 at gene expression level in the three BCa cells. Values shown were mean ± SD of triplicate measurements and 
repeated three times with similar results. Statistical significance was calculated using ANOVA. **p < 0.01. (C) Representative double 
immunofluorescence staining of TRPM7 (green) and GAPDH (red) in the 5637 cells after siTRPM7 treatment (KD) (b), comparing with 
siCON treatment (NC) (a). Nuclears were stained by TOTO-3 (blue). The images were photographed by confocal microscopy. The scale 
bar for C (a-b) is 10 μm. The effect on EMT markers (E-cadherin, N-cadherin and Vimentin) in the BCa cells by TRPM7 deficiency was 
investigated by Western blot and double immunofluorescence staining analysis. (D) Protein abundance of E-cadherin was increased by 
the siTRPM7 treatment in the three cell lines, in contrast, a reduce of N-cadherin and Vimentin was noted by the Western blot analysis. 
GAPDH abundance was used as a control. Cell types, treatment of siRNA and protein masses were indicated. (E–G) Representative double 
immunofluorescence staining for E-cadherin (E), N-cadherin (F) and Vimentin (G) (green) in the 5637 cells after siTRPM7 treatment (KD) 
(b) compared with siCON treatment (NC) (a). Nuclears were stained by DAPI (blue). The images were photographed by fluorescence 
microscopy. The scale bars for E-G are 15 μm.
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Figure 4: TRPM7 deficiency inhibited BCa cells migration and invasion through PI3K/AKT pathway. (A) Cell migration 
and invasion were evaluated by transwell assay for the parental, siCON- and siTRPM7-treated BCa cells by the transwell chamber system. 
Migrative and invasive cells were fixed and stained with crystal violet. Scale bar is 100 µm. The relative cell number of migration (B) and 
invasion (C) in each cells was statistically analyzed. Cell types and treatment of siRNA were indicated. (D) Migration of parental, siCON- 
and siTRPM7-treated BCa cells was determined at 0, 12 and 24 h by wound healing assay and the gap closure was statistically analyzed (E). 
All values for statistical analysis shown were mean ± SD of triplicate measurements and repeated three times with similar results. Statistical 
significance was calculated using ANOVA. *p < 0.05, **p < 0.01. (F) Western blot analysis for protein abundance of phosphorylated and 
total PI3K, AKT, FAK, as well as MMP2/9 in parental, siCON- and siTRPM7-treated BCa cells. GAPDH was used as a loading control (cell 
types, treatment of siRNA and protein masses were indicated). 
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Figure 5: Downregulation of TRPM7 repressed cell proliferation by triggering cell cycle arrest at G0/G1 phase in the 
BCa cells. (A) Viability of cells transfected with siTRPM7 from day 1 until day 5 was analyzed by CCK-8 assay, comparing with siCON 
and parental cells. (B) Flow cytometry analysis for the BCa cells treated with siTRPM7 for 48 h compared with siCON and parental cells. 
Percentages (%) of cell populations at different stages of cell cycles were listed within the panels. All histograms revealed the percentage 
(%) of cell populations from three independent experiments. Cell types and treatment of siRNA were indicated. *p < 0.05, **p < 0.01. 
(C) Downregulation of protein abundance involved in the cell cyle regulation (CDK2, CDK4 and CCND1, also written as Cyclin D1) in 
the BCa lacking TRPM7 was revealed by Western blot analysis. GAPDH abundance was used as a control. Cell types, treatment of siRNA 
and protein masses were indicated. 
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caspase 3, a downstream protein of BCL2 and BAX in the 
apoptotic cascade [47], was decreased, and its active form 
cleaved-caspase 3 was increased (Figure 6C). Moreover, 
we have found that Cytochrome C was also upregulated, 
suggesting that TRPM7 deficiency could trigger BCa cell 
apoptosis through a mitochondrial-dependent manner [48] 
(Figure 6C). Another key family, the MAPK including 
ERK1/2, JNK and p38, which are involved in the 
development and apoptosis regulation of tumor cells, was 
also altered in the siTRPM7-treated BCa cells (Figure 6D). 
TRPM7 deficiency strongly induced phosphorylated 
ERK1/2 (p-ERK1/2) in the BCa cells, with only a mild 
impact on p-JNK and p-p38. 
Downregulation of TRPM7 induced BCa cell 
apoptosis through activation of ERK1/2
We have pre-treated the BCa cells using U0126 
to repress the activity of ERK1/2 and transfected with 
siTRPM7 and controls, revealing a significant recovery of 
cell growth delay triggered by TRPM7 deficiency in all the 
three BCa cells indicated by the CCK-8 assay (Figure 7A). 
Importantly, flow cytometry analysis exhibited that 
deactivation of ERK1/2 through pre-treatment with the 
U0126 (Figure 7B), could reverse TRPM7 deficiency 
induced apoptosis (statistically analyzed in Figure 7C), as 
demonstrated by reduced p-ERK1/2 and reversed BAX/
Figure 6: TRPM7 deficiency induced BCa cell apoptosis via ERK1/2 pathway. (A) Representative flow cytometry analysis of 
apoptosis stained with Annexin V and PI in parental, siCON- and siTRPM7-transfected BCa cells. (B) Statistical analysis of apoptotic rate 
(%) in the three BCa cell lines after the siRNA treatment. Cell types and treatment of siRNA were indicated. The values shown were mean ± SD 
of triplicate measurements and repeated three times with similar results. Statistical significance was calculated using ANOVA. **p <0.01. 
(C) Western blot analysis for proteins involvement in mitochondrial dependent apoptotic pathway, such as BAX, BCL2, Cytochrome 
C and related proteins pro-caspase 3 and cleaved-caspase 3. (D) Proteins in the MAPK family were affected indicated by Western blot 
analysis. Phosphorylated and total ERK1/2, JNK and p38 at protein level was analyzed, suggesting a dominated activation of ERK1/2 in 
the MAPK family by the siTRPM7. GAPDH abundance was used as a control. Cell types, treatment of siRNA and protein masses were 
indicated. 
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BCL2 ratio, as well as decreased Cytochrome C and 
cleaved-caspase 3 using Western blot analysis (Figure 7D). 
Reduction of either TRPM7 protein activity 
by carvacrol or TRPM7 gene transcription by 
lentiviral-shRNA could inhibit bladder cancer 
growth in vivo
To further analyze the effects of TRPM7 activity 
in BCa tumorigenesis in vivo, a NOD/SCID mouse 
model transplanted with T24 cells was established 
(Figure 8A– 8B). Two weeks after the transplantation, 
carvarcrol was intraperitoneally injected in the mice to 
inhibit the activity of TRPM7 (Figure 8A–8B, b). In 
contrast, other mice transplanted with T24 were injected 
by saline as control (Figure 8A–8B, a). The difference of 
tumor size for the carvacrol treated mice and the control 
mice was statistically analyzed in Figure 8C, suggesting 
a reduced tumor growth by the deactivation of TRPM7 
protein in vivo. In addition, we also transplanted the 
T24 cells infected with lentiviral-TRPM7-shRNA 
(T24 LV-M7sh) to observe the tumor growth under 
downregulation of TRPM7 at transcriptional level 
(Figure 8D–8E). We noticed significantly decreased 
tumor size (Figure 8F) and weight (Figure 8G) triggered 
by TRPM7 deficiency comparing with the control group 
(T24 LV-NC). 
Overexpression of TRPM7 induced BCa cell 
proliferation and motility
BCa cells (T24 and EJ) were transfected with 
pcDNA5/FRT/TO/HA-TRPM7 vector to overexpress 
TRPM7 (Supplementary Figure S3A), which could trigger 
significantly increased cell proliferation revealed by 
CCK- 8 assay (Supplementary Figure S3B) and clonogenic 
survival assay (Supplementary Figure S3C). Induction 
of T24 and EJ cell migration rates was suggested by 
transwell migration assay, confirmed by the statistically 
analysis (Supplementary Figure S3D). 
DISCUSSION
The TRPM family, an essential family of proteins 
exhibited distinct functions on tumorigenesis [49, 50]. Our 
group has reported that the TRPM family could regulate 
cell cycle and growth in human osteosarcoma and prostate 
cancer cells [32, 51]. The present study aims to investigate 
Figure 7: Recovering siTRPM7-induced BCa cell apoptosis by U0126 to deactivate ERK1/2. (A) T24, EJ, 5637 cells were 
pre-treated by U0126 at 10 mM for 2 h and treated by siTRPM7 for 48 h, comparing with siCON and parental cells. Proliferation of the BCa 
cells were analyzed by CCK-8 assay. Cell types and treatment of siRNA were indicated. *p < 0.05, **p < 0.01. (B) Apoptotic cells staining 
with Annexin V and PI were revealed by flow cytometry analysis and the apoptotic rates were statistically analyzed (C). Values of statistical 
data shown were mean ± SD of triplicate measurements and repeated three times with similar results. Statistical significance was calculated 
using ANOVA. *p < 0.05, **p < 0.01. (D) Western blot analysis for phosphorylated and total ERK1/2 as well as mitochondrial dependent 
apoptotic pathway proteins (BAX, BCL2, Cytochrome C, pro-caspase 3 and cleaved-caspase 3). GAPDH abundance was used as a control. 
Cell types, treatment of siRNA and protein masses were indicated. 
Oncotarget72950www.impactjournals.com/oncotarget
Figure 8: Deactivation of TRPM7 by carvacrol and decreased TRPM7 by lentiviral-shRNA suppressed bladder cancer 
growth in vivo. (A) Nude mice were subcutaneously transplanted with T24 cell for 14 days, and continueouslly intraperitoneally injected 
by carvacrol for 28 days (b) compared with injection by saline (a) as a control. (B) Dissected tumor from the nude mice injected by 
carvacrol (b) and saline (a). (C) Statistical analysis of tumor size (mm3) measured by a caliper and calculated using t-test, *p < 0.05. Days 
after T24 cell transplantation, tumor size and saline / carvacrol injection were indicated. (D) Nude mice were subcutaneously transplanted 
with T24 cell infected by lentiviral-TRPM7-shRNA (T24 LV-M7sh) for 42 days (b) compared with lentiviral-control-shRNA (T24 LV-NC) 
(a). (E) Dissected tumor from the nude mice injected by lentiviral-TRPM7-shRNA (T24 LV-M7sh) (b) and lentiviral-control-shRNA (T24 
LV-NC) (a). Statistical analysis of tumor size (F) and tumor weight (G), calculated using t-test, *p < 0.05, **p < 0.01. Days after T24 cell 
transplantation, tumor size and types of lentiviral-shRNA infection were indicated. 
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the effect and mechanism of TRPM7, an important TRPM 
family member involved in Ca2+-permeable channel, on 
human bladder cancer, which remains largely unknown yet. 
Microarray analysis using human bladder cancer tissues 
compared with normal bladder epithelium tissues has 
suggested a close correlation between calcium signaling 
pathway and bladder cancer via MAPK signaling pathway, 
confirmed by overrepresentation using microarray raw data 
and DAVID database. We analyzed gene expression and 
protein abundance of TRPM7 in BCa tissues, observing 
a strong upregulation of TRPM7 at the gene expression 
and protein level by double immunofluorescence staining 
analysis, co-localized with OCT-4, a potential marker for 
BCa cells [52, 53]. Moreover, we noticed the upregulation 
of TRPM7 may be correlated with the EMT markers in the 
BCa tissue, which could reveal the malignancy of tumor 
[54, 55]. 
We have selected three typical BCa cell lines 
with distinguished malignancy, T24, EJ and 5637, to 
generate the BCa cell model with TRPM7 deficiency 
using siRNA transfection. Indeed, we confirmed that 
knockdown of TRPM7 in the three BCa cell lines at gene 
expression and protein levels. Moreover, downregulation 
of TRPM7 resulted in a reversed status for the EMT 
markers, suggesting deficiency of TRPM7 could alleviate 
malignancy of BCa. Furthermore, our results revealed a 
significant increase of ROS status and protein abundance 
involved in the ROS metabolism in the BCa cells with 
downregulated TRPM7, suggesting a correlation between 
TRPM7 and ROS in BCa cells. 
Knockdown of TRPM7 could reverse EMT markers 
in the three BCa cells, and we also observed that TRPM7 
deficiency could also inhibit migration and invasion of 
BCa cells, as EMT has been reported to play a critical role 
in cancer cell migration and invasion [56]. To confirm the 
effect triggered by siTRPM7 treatment, we have established 
a BCa cell model with TRPM7-overexpression and noticed 
the migration rate was significantly increased. Moreover, 
treatment of siTRPM7 could also reduce MMP2/9 and 
phosphorylated FAK, PI3K, AKT in the BCa cells. Recent 
studies suggested FAK is a participant in focal adhesion 
dynamics between cells, playing a key role in cell motility 
[57] and MMPs could degrade the extracellular matrix 
and promote cancer cells to metastasize [58, 59]. Another 
publications reported that PI3K/AKT is a key signaling 
pathway [60, 61], which was deactivated by the TRPM7 
deficiency in our study as well, suggesting that inhibited 
BCa cell motility triggered by TRPM7 knockdown could 
be via the PI3K/AKT signaling pathway. 
A major effect of TRPM7 was to induce delayed cell 
proliferation, cycle arrest at G0/G1 phase and apoptosis in 
the BCa cells with TRPM7 deficiency. Proteins involved 
in cell cycle regulation, CCND1 and CDK2/4, were all 
reduced after the siTRPM7 treatment. Moreover, proteins 
involved in apoptosis were strongly altered, especially 
imbalance of the BAX/BCL2 ratio, which is involved 
in mitochondrial-dependent apoptosis [62, 63], and 
related proteins including cleaved-caspase 3 [64, 65] and 
Cytochrome C [66, 67], suggesting that TRPM7 deficiency 
could trigger a mitochondrial-mediated apoptosis. 
Importantly, as suggested by our microarray analysis, 
MAPK signaling pathway, a central regulator in the 
pathway network, could be altered by the affected calcium 
signaling pathway due to TRPM7 knockdown. Western 
blot analysis indicated ERK1/2, a member of MAPK 
family, was remarkably increased in the phosphorylated 
form, suggesting knockdown of TRPM7 might induce a 
mitochondrial dependent apoptosis via ERK1/2, which 
could be activated by phosphorylation on specific sites and 
promote either intrinsic or extrinsic apoptotic pathways 
by induction of mitochondrial Cytochrome C release 
or caspase-8 activation, permanent cell cycle arrest or 
autophagic vacuolization [68]. 
Therefore, we deactivated ERK1/2 by pre-treatment 
of U0126 in the three BCa cells and noticed a decrease of 
the p-ERK1/2 at protein level. Furthermore, the delayed 
cell growth caused by siTRPM7 was reversed significantly, 
and the apoptotic cell rates were significantly reduced by 
ERK1/2 inhibition, as well as the proteins involved in 
the apoptosis pathway were recovered to the level of the 
control group. Importantly, we have established a T24-
transplanted NOD/SCID mouse model with carvacrol [69] 
and lentiviral-shRNA treatment respectively, observing a 
significant delayed tumor growth by both reduction of 
TRPM7 protein activity and TRPM7 gene transcription. 
Therefore, our results in vitro and in vivo have revealed 
that the downregulation of TRPM7 could reduce the BCa 
cell proliferation, trigger cell cycle arrest and apoptosis. 
In conclusion, downregulated TRPM7 could reduce the 
activity of bladder cancer cells and induce cell apoptosis 
via ERK1/2 pathway. 
MATERIALS AND METHODS
Ethical statement for human bladder tissue 
samples
Three stage II bladder cancer tissue samples and 
three normal bladder tissue samples were collected from 
male patients (ages 62 ± 1.581) after surgery by radical 
resection and male donors (ages 37 ± 2.327) undergoing 
transplant by accidental death, at Zhongnan Hospital of 
Wuhan University, Wuhan, China. Informed consent was 
obtained from all subjects to collect the samples from the 
operating room and to store them in liquid nitrogen for 
total RNA isolation, as well as to fix the samples in 4% 
Paraformaldehyde (PFA) for immunofluorescence staining 
analysis. The study was approved by the Ethics Committee 
at Zhongnan Hospital of Wuhan University (approval 
number: 2015029, Supplementary Information S1) and the 
sample collection as well as treatment were carried out in 
accordance with the approved guidelines. 
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Ethical statement for NOD/SCID mice
Investigation has been conducted in accordance with 
the ethical standards and according to the Declaration of 
Helsinki and according to national and international 
guidelines and has been approved by the author’s 
institutional review board. Male NOD/SCID mice in this 
study were purchased from Beijing HFK Bioscience Co., 
Ltd. in Beijing, China (http://www.hfkbio.com/en/).
Human bladder cancer cell lines
Human bladder cancer cell lines EJ cells (carcinoma, 
Cat. #CL-0274) and BIU-87 (Cat. #CL-0035) were 
purchased from the Procell Co., Ltd. in Wuhan, China. 
The T24 (transitional cell carcinoma, Cat. #SCSP-536), 
5637 (grade II carcinoma, Cat. #TCHu1), UM-UC-3 
(Cat. #TCHu217), RT-4 (Cat. #TCHu226) and SV-HUC-1 
(Cat. #TCHu169) were kindly provided by the Stem Cell 
Bank, Chinese Academy of Sciences in Shanghai, China. 
Identification of the BCa cell lines was at the China Centre 
for Type Culture Collection in Wuhan, China. The EJ, 
BIU-87, T24, 5637 and SV-HUC-1 cells were cultured in 
RPMI-1640 medium (Gibco, China), UM-UC-3 cells were 
cultured in DMEM medium (Gibco, China) and RT-4 cells 
were cultured in McCoy's 5A Medium (Gibco, China) 
containing 1% penicillin G sodium/streptomycin sulphate 
and 10% fetal bovine serum (FBS) (Gibco, Australia) in 
a humidified atmosphere consisting of 95% air and 5% 
CO2 at 37ºC.
RNA expression analyses
Total RNA isolation from bladder tissues and 
BCa cells
Total RNA was isolated from bladder tissues and 
distinct BCa cells using the Qiagen RNeasy Mini Kit 
(Cat #74101), combined with QIAshredder from Qiagen 
(Cat #79654) using a centrifuge (Eppendorf, Cat #5424) 
to increase the quantity and quality of isolated total 
RNA, according to the manufacturer’s protocol. Each 
RNA sample was digested by DNase I (RNase-Free 
DNase Set, Qiagen, Cat #79254) to remove possible 
contamination of genomic DNA. The quantity of isolated 
RNA was measured by a NanoDrop® ND-1000 UV-Vis 
spectrophotometer (Thermo Scientific, USA).
Microarray analysis of mRNA isolated from 
human bladder tissues
Our group has established a microarray analysis 
using mRNA isolated from the three stage II bladder cancer 
tissues and the three normal bladder tissues, as described 
by Wang et al. in 2016 [2]. Briefly, according to the 
standard Affymetrix protocol, 250 ng total RNA of each 
sample was prepared to biotinylated cDNA by Ambion® 
WT Expression Kit. On GeneChip Human Transcriptome 
Array 2.0, 5.5 µg of cDNA were hybridized for 16 h at 
45ºC, continuously washed and stained in the Affymetrix 
Fluidics Station 450, scanned by using Affymetrix® 
GeneChip Command Console (AGCC) installed in 
GeneChip® Scanner 3000 (7G). Data analysis was with 
a Robust Multichip Analysis (RMA) algorithm using 
Affymetrix default analysis settings and global scaling 
as normalization method. By Gene ontology (GO) and 
pathway-Relation-Network (Path-net) analysis tools based 
on Kyoto Encyclopedia of Genes and Genomes (KEGG) 
Pathway Database using Gene Cloud of Biotechnology 
Information (GCBI Plateform, Shanghai, China) [70], 
genes and pathways correlated with bladder cancer were 
generated. The resulting gene list was subjected to the 
Database for Annotation, Visualization and Integrated 
Discovery (DAVID) [71] as well for annotation and 
overrepresentation analysis of the genes involved in 
calcium signaling pathway (Supplementary Figure S2). 
The microarray data was submitted to the Gene Expression 
Omnibus (GEO) database with accession number 
GSE76211. All data are MIAME compliant.
Reverse transcription and quantitative real time 
PCR (qRT-PCR)
1 µg of total RNA isolated from bladder tissues 
or BCa cells was mixed with oligo (dT) 12–18 primers 
to synthesize first-strand cDNA by using RevertAid 
First Strand cDNA Synthesis Kit (Thermo Scientific, 
China). 1 µg cDNA were used for each reaction of the 
polymerase chain reactions (PCR) in a final volume of 
20 µl. All primers conducted with the SYBR Premix 
Ex Taq II (Takara Bio, China) were tested for optimal 
annealing temperatures and PCR conditions were 
optimized with gradient PCRs on a Bio-Rad iCycler (Cat. 
#CFX96). Primer sequences and annealing temperatures 
are summarized in Table 1. Values were normalized for 
amplified β-actin alleles. Relative gene abundance = 2-DDct, 
Dct = cttarget gene - ctβ-actin, for BCa cells DDct = DctsiRNA-treated 
- DctsiRNA-untreated, for bladder tissues DDct = DctBCa tissues - 
Dctnormal bladder tissues (ct = threshold cycle).
Cell culture experiments
Knockdown and overexpression of TRPM7 in the 
BCa cells
TRPM7-target specific small interfering RNA 
(siRNA) and lentiviral small hairpin RNA (LV-shRNA) 
were synthesized by Genepharma Ltd. in Suzhou, 
China. Distinct BCa cells (T24, EJ and 5637) were 
transfected with TRPM7-siRNA (siTRPM7) using 
lipofectamine 2000 (Invitrogen, USA), according to the 
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manufacturer’s protocol. The sense sequence of TRPM7-
siRNA (siTRPM7) / TRPM7-shRNA (shTRPM7) was 
5′-GUCUUGCCAUGAAAUACUCTT-3′, and the sense 
sequence of control-siRNA (siCON) / control-shRNA 
(shCON) was 5′-UUCUCCGAACGUGUCAGGUTT-3′. 
After transfection by siTRPM7 for 48 h, alterations of 
TRPM7 at transcriptional and protein levels were evaluated 
by the qRT-PCR, Western blot and immunofluorescence 
staining analysis. The BCa cells infected by lentiviral-
TRPM7-shRNA (LV-M7sh) and lentiviral-control-shRNA 
(LV-NC) were treated by 0.8 mg/ml puromycin (Sigma, 
USA) for 14 days to select the antibiotic-resistant cells 
xenotransplanted into NOD/SCID mice. 
The plasmid of TRPM7-overexpression (pcDNA5/
FRT/TO/HA-TRPM7 vector) was a gift from Professor 
Loren W. Runnels at University of Medicine & Dentistry of 
New Jersey, USA. The cell model of TRPM7-overexpression 
was established according to Su et al. [72] from the group of 
Professor Runnels. Briefly, the BCa cells (EJ and T24) were 
transfected by the pcDNA5/FRT/TO/HA-TRPM7 vector 
and induced by 1 mg/ml tetracyclines for 48 h. 
Pre-treatment using MKK inhibitor for rescue 
experiments
Before siRNA transfection, BCa cells were pre-
treated by MKK inhibitor U0126 (Sigma, USA) at 10 mM 
for 2 h to deactivate ERK1/2 [13, 73, 74]. BCa cells in 
the untreated group were pre-incubated with appropriate 
amount of vehicle (0.1% DMSO). Both groups were 
submitted for the RNA interference and alterations of cell 
viability and apoptosis were measured by CCK-8 assay 
and flow cytometry analysis, respectively. 
Wound healing assay
When the BCa cells grew to 95% confluence, a 200 
µl pipette tip was used to scratch a wound to cell monolayer. 
After scratching, cells were washed with PBS several times 
to remove non-adherent debris, then 0.5% FBS medium 
was added to allow cells to move into the gap without the 
influence of serum. Four different equidistant points of the 
scratched area were photographically measured and imaged 
by an inverted phase contrast microscope (Leica, Cat. #DMI 
1) at 0 h, 12 h and 24 h. Migration rate was calculated as the 
proportion of initial scratch distant of each sample using the 
mean distance between both borderlines that remain cell-free 
after cell migration.
Transwell migration assay
A 24-well plate transwell chamber system (Corning, 
USA) with 8.0 µm pore size was used. Cells were 
suspended in 0.5% FBS medium at a density of 5 × 105 
cell/ml and 100 µl cell suspension was seeded in the upper 
chamber insert without ligand, while the lower chamber 
was filled with 10% FBS medium. After 24 h incubation 
at 37ºC, cells on the upper insert were removed by cotton 
Table 1: List of primers for qRT-PCR
Gene Symbol Forward primer (5′–3′) Reverse primer (5′–3′)
Annealing 
temperature 
(°C)
Length 
(bp)
Transient receptor 
potential melastatin 7
TRPM7 5′- TGGATGATGGC 
ACTGTTGGAA -3′
5′- CATTTGGCCC 
ACCCTCAAATATAA -3′
56 144
Actin, beta ACTB 5′- AGAGCTACGA 
GCTGCCTGAC -3′
5′- AGCACTGTGTT 
GGCGTACAG -3′
56 184
calcium/calmodulin 
dependent protein 
kinase II beta
CAMK II B 5′- GCACACCA 
GGCTACCTGTC -3′
5′- GGACGGGAAG 
TCATAGGCA -3′
56 179
calmodulin 1 CALM1 5′- TTGACTTCCCC 
GAATTTTTGACT -3′
5′- GGAATGCCTCA 
CGGATTTCTT -3′
56 81
calmodulin 3 CALM3 5′- GACCATTGAC 
TTCCCGGAGTT -3′
5′- GATGTAGCCATT 
CCCATCCTTG -3′
56 118
protein phosphatase 3 
catalytic subunit alpha
PPP3CA 5′- CCAAGTCACC 
GGCTTACAG -3′
5′- CCTCCTTCATAA 
GATGCGCCTT -3′
56 88
protein phosphatase 3 
catalytic subunit beta
PPP3CB 5′- CCCCAACACATC 
GCTTGACAT-3′
5′- GGCAGCACCCT 
CATTGATAATTC -3′
56 140
protein phosphatase 3 
catalytic subunit gamma
PPP3CC 5′- ACCGCGTCATC 
AAAGCTGT-3′
5′- CTTCCAGTCGT 
CCTTCCTTTAC -3′
56 125
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swabs, and cells that migrated to the lower side were fixed 
with 4% PFA and stained with crystal violet. Then the 
chambers were placed under an inverted phase contrast 
microscope and 16 random areas were selected to observe 
and count the migrated cells.
Transwell invasion assay
In transwell invasion analysis, 40 µl ECM gel 
solution (Sigma, USA) diluted to a concentration of 
1 mg/ml was coated on the surface of the upper insert of 
Transwell chamber and placed in a 37ºC incubator for 
overnight. BCa cells were then suspended in 0.5ºC FBS 
medium at a density of 8 × 105 cell/ml and 100 µl cell 
suspension was seeded in the upper chamber insert. After 
incubation 48 h at 37ºC, cells were fixed, stained and 
counted under an inverted phase contrast microscope.
CCK-8 assay
Cell Counting Kit-8 (Roche Biochemicals, Germany) 
was used for cell viability measurement. 100 µl cell 
suspensions (2 × 104 cells per ml) with 10% FBS medium was 
seeded to a 96-well plate and incubated for 5 days at 37ºC. 
Then, 10 µl CCK-8 reagent was added to each well at the 
indicated time and incubated for 4 h at 37ºC. Absorbance was 
measured at 450 nm by a Rayto-6000 system (Rayto, China).
Clonogenic survival assay
BCa cells were seeded in 6-well plates (1500 cells 
per well) and grew into colonies for approximately 
15 days. Colonies were emerged and fixed by 4% PFA for 
30 min, staining with crystal violet, counted and defined as 
aggregates of 50 or more cells and photographed. 
Flow cytometry analysis for alterations of cell 
cycle and apoptosis
For cell cycle analysis, 1 × 106 cells were harvested 
and fixed in 70% ice cold ethanol at –20ºC for overnight. 
After centrifugation, pellets were resuspended with PBS 
containing 50 µg/ml propidium iodide (Sigma-Aldrich, USA) 
and 0.1 mg/ml RNaseA (20 μg/ml in PBS) in the dark. After 
incubation at 37ºC for 30 min, the DNA content distribution 
was analyzed by flow cytometry analysis (Beckman, Cat. 
#FC500). For apoptosis analysis, after transfection for 48 
h, cells were collected, washed with PBS, and stained with 
FITC Annexin V Apoptosis Detection Kit I (BD biosciences, 
USA) and analyzed by the flow cytometry analysis.
ROS detection by staining with DCFH-DA
The fluorescent probe 2′,7′-Dichlorofluorescin 
diacetate (DCFH-DA) was used to evaluate intracellular 
ROS levels. BCa cells transfected with siTRPM7 and 
siCON were used for this experiment. After transfection 
of cells and growth for 48 h, 10 µmol of DCFH-DA 
(Sigma, USA) was added to 2 ml medium, and incubated 
at 37°C for 30 min. Thereafter, the cells were washed 
three times with PBS and submitted to flow cytometry 
analysis. For ROS staining, slides with the BCa cells were 
stained by DCFH-DA and incubated for 30 min at room 
temperature, then washed by PBS three times. Nuclei 
were counterstained with 1 µM DAPI for 20 min at room 
temperature. Images were taken with a fluorescence 
microscope (Olympus, Cat. #IX73).
Protein analyses
Isolation of total protein from BCa cells and 
Western blot analysis
The BCa cells (T24, EJ and 5637) were sonicated 
and lysed in RIPA buffer containing protease inhibitor 
and phosphatase inhibitor (Sigma-Aldrich, USA) on ice 
for 30 min, then centrifuged at 12,000 g for 15 min to 
collect supernatant. By Bradford protein assay (Bio-Rad, 
Germany) the concentrations of protein were determined 
using Bovine serum albumin (BSA) as standard. The 
isolated total protein was resolved using 6–15% SDS-
PAGE and transferred to PVDF membrane (Millipore, 
USA). Membranes were blocked by 5% non-fat milk 
and incubated with primary antibodies (Table 2) at 4°C 
for overnight. After washing, the membranes were 
incubated with secondary antibody (listed in Table 3) at 
room temperature for 2 h. Bands were visualized using an 
enhanced chemiluminescence (ECL) kit (Bio-rad, USA) 
and detected by Kodak Biomax MR films. 
Immunofluorescence staining for human bladder 
tissue samples
Histological diagnosis of bladder tissues were 
examined by two experienced pathologists independently. 
All the samples were fixed by 4% PFA at 4ºC overnight and 
embedded into paraffin (Paraplast, Sigma-Aldrich) using 
tissue processor (Thermo Fisher Scientific, Cat. #STP 120). 
Paraffin sections (4 μm) were cut with a rotation microtome 
(Thermo Fisher Scientific, Cat. #HM325). The sections were 
serially incubated with indicated primary antibody (listed 
in Table 2) and Cy3-labeled or FITC- labeled secondary 
antibody (listed in Table 3) in humidified atmosphere. Nuclei 
were labeled with DAPI (2 μg/ml). Sections were analyzed 
by a fluorescence microscope (Olympus, Cat. #IX73).
Immunofluorescence analysis for BCa cells
BCa cells were seeded on 12 mm coverslips, washed 
three times with ice cold PBS and fixed with 4% PFA for 
30 min. Cells were then treated with 0.1% Triton X-100 
solution and blocked in normal goat serum for 30 min at 
room temperature. Afterwards, cells were incubated with the 
indicated primary antibody (Table 2) at the proper dilution 
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Table 2: List of primary antibodies
Antigens Species antibodies raised in
Dilution 
(IF) Dilution (WB) Supplier
Akt (pan), mouse Rabbit, monoclonal - 1:2,000 Cell Signaling Technology, USA, Cat. #4691
Bax, human Rabbit, monoclonal - 1:2,000 Cell Signaling Technology, USA, Cat. #5023
Bcl-2, human Rabbit, monoclonal - 1:2,000 Cell Signaling Technology, USA, Cat. #2872
Caspase-3, human Rabbit, monoclonal - 1:2,000 Cell Signaling Technology, USA, Cat. #9665
Cytochrome c, human Rabbit, monoclonal - 1:500 Cell Signaling Technology, USA, Cat. #4280
CDK2, human Rabbit, monoclonal - 1:2,000 Cell Signaling Technology, USA, Cat. #2546
CDK4, human Rabbit, monoclonal - 1:2,000 Cell Signaling Technology, USA, Cat. #12790
Cleaved Caspase-3, human Rabbit, monoclonal - 1:500 Cell Signaling Technology, USA, Cat. #9664
Cyclin D1, human Rabbit, monoclonal - 1:2,000 Cell Signaling Technology, USA, Cat. #2978
E-cadherin, human Rabbit, monoclonal 1:200 1:500 Cell Signaling Technology, USA, Cat. #3195
FAK, human Rabbit, monoclonal - 1:1,000 Cell Signaling Technology, USA, Cat. #13009
Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), 
human
Mouse, monoclonal 1:200 1:2,000 Santa Cruz Biotechnology Inc., USA, Cat. #sc-365062
MMP-2, human Rabbit, monoclonal - 1:500 Cell Signaling Technology, USA, Cat. #13132
MMP-9, human Rabbit, monoclonal - 1:1,000 Cell Signaling Technology, USA, Cat. #13667
N-cadherin, human Rabbit, monoclonal 1:200 1:1,000 Cell Signaling Technology, USA, Cat. #13116
OCT-4, human Rabbit, monoclonal 1:200 1:1,000 Cell Signaling Technology, USA, Cat. #2750
OCT-4, human                                     Mouse, monoclonal 1:200 - Novus Biologicals, USA, Cat. #NB110-90606
p38 MAPK, human Rabbit, monoclonal - 1:2,000 Cell Signaling Technology, USA, Cat. #8690
p44/42 MAPK (Erk1/2), rat Rabbit, monoclonal - 1:2,000 Cell Signaling Technology, USA, Cat. #4695
Phospho-Akt (Ser473), 
human Rabbit, monoclonal - 1:1,000
Cell Signaling Technology, USA, 
Cat. #4060
Phospho-FAK (Tyr397), 
human Rabbit, monoclonal - 1:1,000
Cell Signaling Technology, USA, 
Cat. #8556
Phospho-p38 (Thr180/
Tyr182), human Rabbit, monoclonal - 1:1,000
Cell Signaling Technology, USA, 
Cat. #4511
Phospho-p44/42 MAPK 
(Erk1/2) (Thr202/Tyr204), 
human
Rabbit, monoclonal - 1:1,000 Cell Signaling Technology, USA, Cat. #4370
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for 2 h at room temperature, washed three times with PBS, 
and incubated with Cy3-labeled or FITC- labeled secondary 
antibody (Table 3) for 1 h. Nuclei were visualized with 
1 mM TOTO-3 iodide for 10 min at room temperature. 
Immunofluorescence staining was analyzed using a confocal 
microscope (Leica, Cat. #SP8). 
Xenograft model 
Male NOD/SCID mice were purchased from Beijing 
HFK Bioscience Co., Ltd. in Beijing, China. Six mice at 
Day 42 were subcutaneously injected with T24 cells at a 
concentration of 4 × 107/ml diluted in PBS (100 µl for each 
mouse) and grown for 14 days [75]. Three mice of them were 
intraperitoneally injected by carvacrol at 50 mg/ml (200 µl 
for each mouse) and repeated for 28 days to inhibit activity 
of TRPM7 [69]. The other three mice were treated by 0.9% 
saline (200 µl for each mouse) for 28 days as control. 
Lentiviral-TRPM7-shRNA and lentiviral-control-
shRNA infected T24 cells were subcutaneously injected to 
ten mice, respectively, diluted in PBS (200 µl per mouse) 
at a concentration of 2 × 107/ml cells. The tumor size for 
each mouse was measured every four days using a caliper 
and counted as: tumor size = length × width2 × 0.5 mm3 
[76]. The growth of the tumor was observed for 42 days, 
and the mice was sacrificed to measure the tumor weight.
Phospho-PI3 Kinase p85 
(Tyr458)/p55 (Tyr199), 
mouse
Rabbit, monoclonal - 1:1,000 Cell Signaling Technology, USA, Cat. #4228
Phospho-SAPK/JNK 
(Thr183/Tyr185), human Rabbit, monoclonal - 1:1,000
Cell Signaling Technology, USA, 
Cat. #4668
PI3 Kinase p85, human Rabbit, monoclonal - 1:1,000 Cell Signaling Technology, USA, Cat. #4257
SAPK/JNK, human Rabbit, monoclonal - 1:2,000 Cell Signaling Technology, USA, Cat. #9252
TRPM7, mouse Mouse, monoclonal 1:100 1:500 Abcam, UK, Cat. #ab85016
Vimentin, human Rabbit, monoclonal 1:200 1:2,000 Cell Signaling Technology, USA, Cat. #5741
Catalase, human Rabbit, monoclonal - 1:2,000 Abcam, UK, Cat. #ab76024
SOD2, human Rabbit, monoclonal - 1;1,000 Abcam, UK, Cat. #ab68155
Table 3: List of secondary antibodies and counterstaining of nuclei
Secondary detection system used Host Method Dilution Supplier
Anti-Mouse-IgG (H+L)-HRP Goat WB 1:10,000 Sungene Biotech, China, Cat. #LK2003
Anti-Rabbit-IgG (H+L)-HRP Goat WB 1:10,000 Sungene Biotech, China, Cat. #LK2001
Anti-rabbit IgG (H+L), 
F(ab’)2 Fragment (Alexa 
Fluor® 488 Conjugate)
Goat IF 1:50 Cell Signaling Technology, USA, Cat. #4412
Anti-rabbit IgG (H+L), 
F(ab’)2 Fragment (Alexa 
Fluor® 555 Conjugate)
Goat IF 1:50 Cell Signaling Technology, USA, Cat. #4413
Anti-mouse IgG (H+L), 
F(ab’)2 Fragment (Alexa 
Fluor® 488 Conjugate)
Goat IF 1:50 Cell Signaling Technology, USA, Cat. #4407
Anti-mouse IgG (H+L), 
F(ab’)2 Fragment (Alexa 
Fluor® 555 Conjugate)
Goat IF 1:50 Cell Signaling Technology, USA, Cat. #4408
Hoechst 33342 nucleic acid staining 
(DAPI)
- IF 1:750 Molecular Probes/Invitrogen, Carlsbad, CA, 
USA, Cat. #A11007
TOTO-3 iodide - IF 1:750 Molecular Probes/Invitrogen, Carlsbad, CA, 
USA, Cat. #T3604
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Statistical analyses
Data were expressed as mean ± SD from three 
independent experiments. All analyses were performed 
three times and represent data from three individual 
experiments. Two-tailed Student’s t-tests and one-way 
analysis of variance (ANOVA) were used to evaluate the 
statistical significance of differences of the data. All of 
the statistical analyses were performed with SPSS16.0. 
The statistical significance was set at probability values 
of p < 0.05.
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